Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases

Neuro Endocrinol Lett. 2020 Apr;41(1):10-16.

Abstract

Case 1 was a 51-year-old man diagnosed with thyrotropin (TSH)-secreting pituitary tumor. The octreotide loading test showed suppression of TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function. Three months after treatment initiation, tumor shrinkage was observed, and pituitary tumor resection was performed through transsphenoidal surgery. Case 2 was a 47-year-old woman in whom the octreotide loading test showed suppressed TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function. After six months of treatment, tumor reduction was observed, and transsphenoidal surgery was performed. In both cases, lanreotide administration before TSH-secreting pituitary tumor resection achieved normalization of thyroid function and tumor shrinkage. Treatment with lanreotide seems effective in patients who show TSH secretion suppression in the octreotide loading test.

Publication types

  • Case Reports

MeSH terms

  • Adenoma / drug therapy*
  • Adenoma / metabolism
  • Adenoma / pathology
  • Adenoma / surgery
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Female
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Peptides, Cyclic / administration & dosage*
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / metabolism
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / surgery
  • Preoperative Period
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*
  • Thyrotrophs / drug effects*
  • Thyrotrophs / metabolism
  • Thyrotrophs / pathology
  • Thyrotropin / metabolism
  • Treatment Outcome

Substances

  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Thyrotropin